Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 6/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ABCC8 | Q09428 | 4/20 | 0.38 |
| ▸ | KCNJ11 | Q14654 | 4/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | VEGFA | P15692 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18300010 | 0.84 | EPAS1 (0.41) | ALDH1A1TDP1TSHRABCC8KCNJ11 | |
| SCHEMBL27757990 | 0.82 | EPAS1 (0.41) | ALDH1A1TDP1TSHRCYP3A4EPAS1 | |
| SCHEMBL27645588 | 0.82 | ALDH1A1 (0.46) | ALDH1A1TDP1TSHRCYP3A4EPAS1 | |
| SCHEMBL2974012 | 0.81 | TDP1 (0.45) | ALDH1A1TDP1TSHREPAS1VEGFA | |
| SCHEMBL18298908 | 0.80 | ALDH1A1 (0.39) | ALDH1A1TDP1EPAS1SMN1; SMN2 | |
| SCHEMBL9550142 | 0.80 | TSHR (0.45) | ALDH1A1TDP1TSHRCYP3A4SMN1; SMN2 | |
| SCHEMBL27724895 | 0.78 | ALDH1A1 (0.42) | ALDH1A1TDP1TSHRCYP3A4EPAS1 | |
| SCHEMBL3520821 | 0.78 | ALDH1A1 (0.64) | ALDH1A1TDP1TSHRCYP3A4EPAS1 | |
| SCHEMBL2612649 | 0.78 | GRIN2D (0.42) | ALDH1A1TDP1TSHRCYP3A4ABCC8 | |
| SCHEMBL3192684 | 0.78 | ALDH1A1 (0.62) | ALDH1A1TDP1TSHRCYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130352-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-05-06 | — | — | US | disclosed |
| WO-2019243533-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130352-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | ALDH1A1 3839/4885TDP1 83/4885TSHR 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.